9 Meters Biopharma, Inc.
NMTRQ
$0.00
$0.000.00%
| 03/31/2023 | 12/31/2022 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 53.50% | -19.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.05% | 23.24% | |||
| Operating Income | -19.05% | -23.24% | |||
| Income Before Tax | -16.25% | -27.53% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -16.25% | -27.53% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -16.25% | -27.53% | |||
| EBIT | -19.05% | -23.24% | |||
| EBITDA | -19.06% | -23.23% | |||
| EPS Basic | -11.22% | -27.05% | |||
| Normalized Basic EPS | -8.09% | -26.83% | |||
| EPS Diluted | -11.17% | -27.10% | |||
| Normalized Diluted EPS | -8.09% | -26.83% | |||
| Average Basic Shares Outstanding | 4.52% | 0.38% | |||
| Average Diluted Shares Outstanding | 4.52% | 0.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
